RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재후보

      AML1-ETO 양성인 양표현형 급성 백혈병의 = A case of biphenotypic acute Leukemia with expression of the AML1-ETO gene rearrangement

      한글로보기

      https://www.riss.kr/link?id=A76373496

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Biphenotypic acute leukemia (BAL) is a subtype of acute leukemia that expresses two different immunophenotypic lineages, most commonly myeloid and either B- or T-lymphoid lineages. This entity has been defined by a scoring system proposed by the European Group for the Immunological Characterization of Leukemias (EGIL). The prognosis of BAL is regarded as being worse than either acute lymphoid or myeloid leukemia that does not show lineage ambiguity. However, a treatment strategy for BAL has not yet been established. We experienced a case of BAL with the t(8;21) translocation, a favorable cytogenetic rearrangement in acute myeloid leukemia (AML). The patient was successfully treated with cytarabine and anthracycline for induction and consolidation. The quantitative value of the AML1-ETO gene decreased after achieving complete hematologic remission. Thus, the AML1-ETO gene rearrangement in BAL may be associated with an acceptable response to the treatment strategy for AML. (Korean J Med 76:617-621, 2009)
      번역하기

      Biphenotypic acute leukemia (BAL) is a subtype of acute leukemia that expresses two different immunophenotypic lineages, most commonly myeloid and either B- or T-lymphoid lineages. This entity has been defined by a scoring system proposed by the Europ...

      Biphenotypic acute leukemia (BAL) is a subtype of acute leukemia that expresses two different immunophenotypic lineages, most commonly myeloid and either B- or T-lymphoid lineages. This entity has been defined by a scoring system proposed by the European Group for the Immunological Characterization of Leukemias (EGIL). The prognosis of BAL is regarded as being worse than either acute lymphoid or myeloid leukemia that does not show lineage ambiguity. However, a treatment strategy for BAL has not yet been established. We experienced a case of BAL with the t(8;21) translocation, a favorable cytogenetic rearrangement in acute myeloid leukemia (AML). The patient was successfully treated with cytarabine and anthracycline for induction and consolidation. The quantitative value of the AML1-ETO gene decreased after achieving complete hematologic remission. Thus, the AML1-ETO gene rearrangement in BAL may be associated with an acceptable response to the treatment strategy for AML. (Korean J Med 76:617-621, 2009)

      더보기

      참고문헌 (Reference)

      1 Bene MC, "The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias" 92 : 596-599, 1998

      2 Mulloy JC, "The AML1/ETO fusion protein promotes the expansion of human hematopoietic stem cell" 99 : 15-23, 2002

      3 Klampfer L, "The AML1/ETO fusion protein activates transcription of BCL-2" 93 : 14059-14064, 1996

      4 Krawter F, "Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patient with core binding factor leukemia" 21 : 4413-4422, 2003

      5 Killick S, "Outcome of biphenotypic acute leukemia" 84 : 699-706, 1999

      6 Matutes E, "Definition of acute biphenotypic leukemia" 82 : 64-66, 1997

      7 Kozlov I, "CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemia with immunophenotypic ambiguity" 163 : 62-67, 2005

      8 Aribi A, "Biphenotypic acute leukemia: a case series" 138 : 213-216, 2007

      9 Frater JL, "Biphenotypic acute leukemia with coexpression of CD79a and markers of myeloid lineage" 127 : 356-359, 2003

      10 He G, "B-lymphoid and myeloid lineages biphenotypic acute leukemia with t(8;21)(q22;q22)" 87 : 132-136, 2008

      1 Bene MC, "The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias" 92 : 596-599, 1998

      2 Mulloy JC, "The AML1/ETO fusion protein promotes the expansion of human hematopoietic stem cell" 99 : 15-23, 2002

      3 Klampfer L, "The AML1/ETO fusion protein activates transcription of BCL-2" 93 : 14059-14064, 1996

      4 Krawter F, "Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patient with core binding factor leukemia" 21 : 4413-4422, 2003

      5 Killick S, "Outcome of biphenotypic acute leukemia" 84 : 699-706, 1999

      6 Matutes E, "Definition of acute biphenotypic leukemia" 82 : 64-66, 1997

      7 Kozlov I, "CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemia with immunophenotypic ambiguity" 163 : 62-67, 2005

      8 Aribi A, "Biphenotypic acute leukemia: a case series" 138 : 213-216, 2007

      9 Frater JL, "Biphenotypic acute leukemia with coexpression of CD79a and markers of myeloid lineage" 127 : 356-359, 2003

      10 He G, "B-lymphoid and myeloid lineages biphenotypic acute leukemia with t(8;21)(q22;q22)" 87 : 132-136, 2008

      11 Jaffe ES, "Acute myeloid leukemias. In Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours" IARC Press 75-107, 2001

      12 박경분, "AML1/ETO-양성 급성골수성백혈병에서 역전사중합효소연쇄반응을 이용한 미세잔존질환 연속측정의 의의" 대한혈액학회 38 (38): 3-23, 2003

      더보기

      동일학술지(권/호) 다른 논문

      동일학술지 더보기

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 계속평가 신청대상 (계속평가)
      2021-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      2018-12-01 평가 등재후보 탈락 (계속평가)
      2017-12-01 평가 등재후보로 하락 (계속평가) KCI등재후보
      2013-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2010-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2008-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2006-05-15 학술지명변경 외국어명 : Korean Journal of Medicine -> The Korean Journal of Medicine KCI등재
      2006-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2003-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2002-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2000-07-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 0.1 0.1 0.1
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.11 0.1 0.259 0.02
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼